On April 6, 2017, from 1:00 pm to 5:00 pm, FDA is conducting a public meeting on Patient-Focused Drug Development (PFDD) for Sarcopenia. FDA is interested in obtaining patient perspectives on the impact of sarcopenia on daily life and patient views on treatment approaches. Registration to attend the meeting must be received by April 6, 2017.
In addition to providing input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on June 6, 2017.
Sarcopenia, or the decline of skeletal muscle tissue with age, is one of the most important causes of functional decline and loss of independence in older adults.